switching between glp-1 agonists Understanding receptor and their impact on drug discovery Frontiers | Clinical perspectives on

In June 2024, the FDA officially approved tirzepatide for the treatment of obesity-associated OSAS, marking the first GLP-1based therapy worldwide to receive this indication (16)

doi: 10.1016/J.EBIOM.2024.105284 105 Izzi-EngbeayaCJonesSCrustnaYMachenahalliPCPapadopoulouDModiMet al

Oral medications are also expected to be much less expensive to manufacture than injectable pens

4 Discussion In conclusion, we found significant over-representation of signals for acute pancreatitis (SMQ: 20000022) over other adverse reactions for all GLP-1 RAs

Beginning on July 1, 2024, the baseline BMI for coverage was increased from 30 (obese) to 40 (severely obese)

Update to a position statement of the American Diabetes Association and the European Association for the study of diabetes